ORIC Pharmaceuticals, Inc. (ORIC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ORIC Pharmaceuticals, Inc. (ORIC) Healthcare & Pipeline Overview

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in precision medicines targeting cancer resistance mechanisms, including inhibitors of CD73 and PRC2. Their focus is on developing orally bioavailable therapies to overcome resistance to existing cancer treatments, positioning them in the competitive oncology market.

What Is the Investment Thesis for ORIC?

ORIC Pharmaceuticals presents a notable research candidate within the biotechnology sector, driven by its focus on developing precision medicines for cancer treatment. The company's clinical-stage pipeline, featuring ORIC-533, ORIC-944, and ORIC-114, targets significant resistance mechanisms in cancer therapy. A key value driver is the potential for these therapies to improve outcomes in patients who have developed resistance to existing treatments. The company's market capitalization of $1.12B reflects investor confidence in its pipeline and approach. Upcoming clinical trial results for its lead candidates represent potential catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. The company's beta of 1.36 indicates higher volatility compared to the market.

Based on FMP financials and quantitative analysis

ORIC Key Highlights

• ORIC-533 is an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
• ORIC-944 is an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer.
• ORIC-114 is a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations.
• ORIC has a license and collaboration agreement with Voronoi Inc.
• ORIC has a license agreement with Mirati Therapeutics, Inc.

Who Are ORIC's Competitors?

ORIC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ORIC's Key Strengths?

• Innovative pipeline of precision medicine therapies.
• Targeted approach to overcoming cancer resistance mechanisms.
• Experienced management team with expertise in drug development.
• Strategic collaborations with leading research institutions.

What Are ORIC's Weaknesses?

• Clinical-stage company with no currently marketed products.
• High reliance on clinical trial outcomes and regulatory approvals.
• Limited financial resources compared to larger pharmaceutical companies.
• High cash burn rate associated with drug development activities.

What Could Drive ORIC Stock Higher?

• Clinical trial results for ORIC-533 in patients with resistance to chemotherapy and immunotherapy.
• Data readout from the ORIC-944 clinical trial in prostate cancer patients.
• Initiation of a Phase 1 clinical trial for a new discovery-stage precision medicine candidate.
• Enrollment and progression of patients in ongoing clinical trials for ORIC's lead drug candidates.
• Advancements in strategic collaborations with Voronoi Inc. and Mirati Therapeutics, Inc.

What Are the Key Risks for ORIC?

• Negative return on equity (-35.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays in the development of ORIC's drug candidates.
• Regulatory setbacks or challenges in obtaining marketing approval from the FDA.
• Competition from other biotechnology and pharmaceutical companies developing similar therapies.
• Dependence on key personnel and the ability to attract and retain talent.
• Financial risks associated with funding ongoing research and development activities.

What Are the Growth Opportunities for ORIC?

• Expansion of ORIC-533 Development: ORIC-533, targeting CD73, represents a significant growth opportunity in overcoming resistance to chemotherapy and immunotherapy. Successful clinical trials and subsequent regulatory approval could position ORIC as a leader in this space. The timeline for potential commercialization depends on clinical trial progress, with potential market entry within the next 3-5 years.
• Advancement of ORIC-944 for Prostate Cancer: ORIC-944, an allosteric inhibitor of PRC2, offers a targeted approach to treating prostate cancer. The prostate cancer therapeutics market is projected to grow, driven by an aging population and increasing diagnosis rates. Positive clinical data and regulatory approval could drive significant revenue growth for ORIC. Development timelines suggest potential market launch in 4-6 years, contingent on clinical trial success.
• Development of ORIC-114 for EGFR/HER2 Mutations: ORIC-114, targeting EGFR and HER2 exon 20 insertion mutations, addresses a critical unmet need in cancer therapy. The market for targeted therapies for these mutations is expanding, driven by advancements in genomic sequencing and personalized medicine. Successful development and commercialization of ORIC-114 could generate substantial revenue. The timeline for potential market entry is approximately 5-7 years, pending clinical trial outcomes and regulatory approvals.
• Strategic Collaborations and Licensing Agreements: ORIC's collaborations with Voronoi Inc. and Mirati Therapeutics, Inc. provide access to novel technologies and expand its research and development capabilities. These partnerships can accelerate the development of new therapies and broaden ORIC's pipeline. The financial impact of these collaborations will depend on the achievement of milestones and the successful commercialization of partnered products. These collaborations represent an ongoing growth opportunity for ORIC.
• Expansion into New Cancer Resistance Mechanisms: ORIC's focus on discovering and developing precision medicines targeting other cancer resistance mechanisms represents a long-term growth opportunity. By identifying and validating new therapeutic targets, ORIC can expand its pipeline and address unmet needs in oncology. This strategy requires ongoing investment in research and development, but it has the potential to generate significant returns in the future. The timeline for developing new therapies targeting novel resistance mechanisms is typically 5-10 years.

What Opportunities Does ORIC Have?

• Expanding pipeline through internal research and development.
• Securing partnerships with larger pharmaceutical companies for commercialization.
• Addressing unmet needs in cancer therapy with novel mechanisms of action.
• Leveraging advancements in genomic sequencing and personalized medicine.

What Threats Does ORIC Face?

• Clinical trial failures and regulatory setbacks.
• Competition from other biotechnology and pharmaceutical companies.
• Changes in regulatory landscape and reimbursement policies.
• Intellectual property challenges and patent disputes.

What Are ORIC's Competitive Advantages?

• Proprietary drug candidates with unique mechanisms of action.
• Strong intellectual property portfolio protecting its drug candidates.
• Expertise in precision medicine and cancer resistance mechanisms.
• Strategic collaborations with leading research institutions and pharmaceutical companies.

What Does ORIC Do?

ORIC Pharmaceuticals, Inc., founded in 2014 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for cancer treatment. The company's mission is to address cancer resistance mechanisms through precision medicine. ORIC's pipeline features several clinical-stage product candidates, including ORIC-533, an orally bioavailable small molecule inhibitor of CD73, designed to combat resistance to chemotherapy and immunotherapy. Additionally, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2), is being developed for prostate cancer. ORIC-114, a brain-penetrant, orally bioavailable, irreversible inhibitor, selectively targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency against exon 20 insertion mutations. Beyond these clinical-stage assets, ORIC is advancing multiple discovery-stage precision medicines targeting other cancer resistance mechanisms. The company has established strategic collaborations, including a license and collaboration agreement with Voronoi Inc. and a license agreement with Mirati Therapeutics, Inc., to bolster its research and development efforts. ORIC's focus on overcoming cancer resistance through targeted therapies aims to improve patient outcomes and address unmet medical needs in oncology.

What Products and Services Does ORIC Offer?

• Develops therapies for the treatment of cancers.
• Focuses on precision medicines targeting cancer resistance mechanisms.
• Creates orally bioavailable small molecule inhibitors.
• Targets CD73 to overcome resistance to chemotherapy and immunotherapy.
• Develops allosteric inhibitors of the polycomb repressive complex 2 (PRC2) for prostate cancer.
• Creates brain penetrant inhibitors targeting EGFR and HER2 mutations.
• Engages in licensing and collaboration agreements to expand research capabilities.

How Does ORIC Make Money?

• Develops and patents novel cancer therapies.
• Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approval from agencies like the FDA for commercialization.
• May out-license or partner with larger pharmaceutical companies for commercialization and distribution.

What Industry Does ORIC Operate In?

ORIC Pharmaceuticals operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation and high-risk, high-reward ventures. The oncology market, in particular, is a significant area of focus, driven by the increasing prevalence of cancer and the demand for more effective and targeted therapies. Companies like ORIC are at the forefront of developing precision medicines that address specific cancer resistance mechanisms. The industry is also influenced by regulatory pathways, clinical trial outcomes, and collaborations with larger pharmaceutical companies. Terns Pharmaceuticals, Inc. (TERN) is also developing cancer therapies.

Who Are ORIC's Key Customers?

• Patients diagnosed with various types of cancer.
• Oncologists and other healthcare professionals who prescribe cancer treatments.
• Hospitals and cancer centers that administer cancer therapies.
• Pharmaceutical companies that may partner with ORIC for drug development and commercialization.

F-Score 2/9Financial Health

ORIC Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 28.82 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -35%Key Financial Metrics

Return on equity for ORIC Pharmaceuticals, Inc. stands at -35.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -31.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 16.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.9%, the inverse of the P/E and a quick read on earnings relative to price.

ORIC Pharmaceuticals, Inc. (ORIC) Valuation Context

Valued at $1.12B, ORIC is classified as a small-cap stock. Relative to its peer group, ORIC's quantitative score of 60/100 is roughly in line with the peer average of 68/100.

FY2026 estForward Outlook

Wall Street analysts project ORIC Pharmaceuticals, Inc. revenue of about $8.2M for fiscal 2026, with EPS near $-1.47. The estimate reflects 11 contributing analysts.

ORIC Financials

ORIC Latest News

ORIC Analyst Consensus

ORIC MoonshotScore

ORIC Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources